

AUG 21 2006

MORRISON | FOERSTER

755 PAGE MILL ROAD
PALO ALTO
CALIFORNIA 94304-1018

TELEPHONE: 650.813.5600
FACSIMILE: 650.494.0792

WWW.MOFO.COM

MORRISON & FOERSTER LLP
NEW YORK, SAN FRANCISCO,
LOS ANGELES, PALO ALTO,
SAN DIEGO, WASHINGTON, D.C.

DENVER, NORTHERN VIRGINIA,
ORANGE COUNTY, SACRAMENTO,
WALNUT CREEK, CENTURY CITY

TOKYO, LONDON, BEIJING,
SHANGHAI, HONG KONG,
SINGAPORE, BRUSSELS

To:

NAME:	FACSIMILE:	TELEPHONE:
Commissioner for Patents U.S. Patent and Trademark Office	(571) 273-8300	(571) 272-4000

FROM: Kimberly A. Bolin
Registration No. 44,546

DATE: August 21, 2006

Number of pages with cover page:	12	
-------------------------------------	----	--

Preparer of this slip has confirmed that facsimile number given is correct: 12056/eag4

Comments:

Attorney Docket No.: 420052000117
Group Art Unit: 1615
Examiner: G. Kishore
Application No.: 09/628,387
Filing Date: August 1, 2000
Inventors: Patrick SOON-SHIONG et al.
Title: METHODS AND FORMULATIONS OF TAXANES

Papers attached:

1. Transmittal Form (1 page)
2. Power of Attorney (1 page)
3. Statement under 37 CFR 3.73(b) (1 page)
4. Copy of Assignment (3 pages)
5. Copy of Certificate of Amendment (2 pages)
6. Copy of Certificate of Merger (3 pages)

To ensure compliance with requirements imposed by the United States Internal Revenue Service, Morrison & Foerster LLP informs you that, if any advice concerning one or more U.S. Federal tax issues is contained in this facsimile (including any attachments), such advice is not intended or written to be used, and cannot be used, for the purpose of (i) avoiding penalties under the Internal Revenue Code or (ii) promoting, marketing or recommending to another party any transaction or matter addressed herein.

CAUTION - CONFIDENTIAL

This facsimile contains confidential information that may also be privileged. Unless you are the addressee (or authorized to receive for the addressee); you may not copy, use, or distribute it. If you have received it in error, please advise Morrison & Foerster LLP immediately by telephone or facsimile and return it promptly by mail.

pa-1088616

RECEIVED
CENTRAL FAX CENTER

002

AUG 21 2006

PTO/SB/21 (09-04)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM


(to be used for all correspondence after initial filing)

		Application Number	09/628,387
		Filing Date	August 1, 2000
		First Named Inventor	Patrick SOON-SHIONG
		Art Unit	1615
		Examiner Name	G. Kishore
Total Number of Pages in This Submission	11	Attorney Docket Number	420052000117

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input checked="" type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address (1 page)	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Other Enclosure(s) (please identify below): <ul style="list-style-type: none"> - Statement under 37 CFR 3.73(b) (1 page) - Copy of Assignment (3 pages) - Copy of Certificate of Amendment (2 pages) - Copy of Certificate of Merger (3 pages) - Facsimile Cover Sheet
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application	<input type="checkbox"/> Remarks	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	MORRISON & FOERSTER LLP (Customer Number 25226)		
Signature			
Printed name	Kimberly A. Bolin		
Date	August 21, 2006	Reg. No.	44,546

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, facsimile no. (571) 273-8300, on the date shown below.

Dated: August 21, 2006

Signature: Elsa Guezlec (Elsa Guezlec)

pa-1088612

PTO/SB/80 (01-06)

Approved for use through 12/31/2008. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO

I hereby revoke all previous powers of attorney given in the application identified in the attached statement under 37 CFR 3.73(b).

I hereby appoint:

Practitioners associated with the Customer Number:

25226

OR

Practitioner(s) named below (if more than ten patent practitioners are to be named, then a customer number must be used):

Name	Registration Number	Name	Registration Number

as attorney(s) or agent(s) to represent the undersigned before the United States Patent and Trademark Office (USPTO) in connection with any and all patent applications assigned only to the undersigned according to the USPTO assignment records or assignment documents attached to this form in accordance with 37 CFR 3.73(b).

Please change the correspondence address for the application identified in the attached statement under 37 CFR 3.73(b) to:

The address associated with Customer Number:

25226

OR

<input type="checkbox"/>	Firm or Individual Name			
Address				
City	State	Zip		
Country	Telephone	Email		


Assignee Name and Address:

Abraxis BioScience, Inc.
2730 Wilshire Boulevard, Suite 500
Santa Monica, California 90403

A copy of this form, together with a statement under 37 CFR 3.73(b) (Form PTO/SB/96 or equivalent) is required to be filed in each application in which this form is used. The statement under 37 CFR 3.73(b) may be completed by one of the practitioners appointed in this form if the appointed practitioner is authorized to act on behalf of the assignee, and must identify the application in which this Power of Attorney is to be filed.

SIGNATURE of Assignee of Record

The individual whose signature and title is supplied below is authorized to act on behalf of the assignee

Signature		Date	8/12/06
Name	Richard E. Maroun	Telephone	(310) 883-3146
Title	Chief Administrative Officer		

Attorney Docket No.: 420052800100

pa-1084039

PTO/SB/08 (09-04)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Patrick SOON-SHIONG et al.Application No./Patent No.: 09/628,387 Filed/Issue Date: August 1, 2000Entitled: METHODS AND FORMULATIONS OF TAXANES

Abraxis BioScience, Inc., a corporation
 (Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. the assignee of the entire right, title, and interest; or
2. an assignee of less than the entire right, title and interest.

The extent (by percentage) of its ownership interest is _____ %
 in the patent application/patent identified above by virtue of either:

- A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

- B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:


Neil P. DESAI and Patrick SOON-

1. From: SHIONG To: VivoRx Pharmaceuticals, Inc.
 The document was recorded in the United States Patent and Trademark Office at
 Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: VivoRx Pharmaceuticals, Inc. To: American BioScience, Inc.
 The document was recorded in the United States Patent and Trademark Office at
 Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: American BioScience, Inc. To: Abraxis BioScience, Inc.
 The document was recorded in the United States Patent and Trademark Office at
 Reel _____, Frame _____, or for which a copy thereof is attached.

 Additional documents in the chain of title are listed on a supplemental sheet. Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.



Signature

8/12-05

Date

Richard E. Maroun

Printed or Typed Name

(310) 883-3146

Telephone Number

Chief Administrative Officer

Title

Attorney Docket No.: 420052000117

pa-1084083

ASSIGNMENT**COPY**

This Assignment is made by Neil P. Desai, Los Angeles, California and Patrick Soon-Shiong, Los Angeles, California assignor(s), to, VIVORX PHARMACEUTICALS, INC., Assignee, having a place of business at 2825 Santa Monica Blvd., Suite 104, Santa Monica, California 90404.

WHEREAS, Assignor(s) have invented a new and useful invention entitled COMPOSITIONS USEFUL FOR ADMINISTRATION OF CHEMOTHERAPEUTIC AGENTS, for which an application for United States Letters Patent, was filed on September 9, 1997 in the United States Patent and Trademark Office and assigned U.S. Serial No.08/926,155.

WHEREAS, Assignor(s) believe themselves to be the original inventor(s) of the invention disclosed and claimed in said application for Letters Patent; and

WHEREAS, the parties desire to have a recordable instrument assigning the entire right, title and interest in and to said invention, said application and any Letters Patent that may be granted for said inventions in the United States and throughout the world;

NOW, THEREFORE, in accordance with the obligations to assign the invention and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor(s) sell(s), assign(s), and transfer(s) to Assignee, the entire right, title, and interest in and to said invention, said application and any Letters Patent that may be granted for said invention in the United States and throughout the world, including the right to file foreign applications directly in the name of the Assignee and to claim for any such foreign applications any priority rights to which such applications are entitled under international conventions, treaties, or otherwise.

Assignor(s) agree that, upon request and without further compensation, but at no expense to Assignor(s), they and their legal representatives and assign(s) will do all lawful acts, including the execution of papers and the giving of testimony, that may be necessary or desirable for obtaining, sustaining, reissuing, or enforcing Letters Patent in the United States and throughout the world for said invention, and for perfecting, recording, or maintaining the title of

2

Assignee; its successors and assigns, to said invention, said application, and any Letters Patent granted for said invention in the United States and throughout the world.

Assignor(s) represent and warrant that they have not granted and will not grant to others any rights inconsistent with the rights granted herein.

Assignor(s) authorize(s) and request(s) the Assistant Commissioner for Patents of the United States and of all foreign countries to issue any Letters Patent granted for said invention, whether on said application or on any subsequently filed division, continuation, continuation-in-part or reissue application, to Assignee, its successors and assigns, as the assignee of the entire interest in said invention.

3

IN WITNESS WHEREOF, Assignor(s) have executed this Assignment on the date(s) provided below.

Assignor : Neil P. Desai

Date: February 25, 1998

Signature

Neil P. Desai

STATE OF California
COUNTY OF Los Angeles

On February 25, 1998 before me, Carol S. Rigsbee, a Notary Public in and for said State, personally appeared Neil P. Desai, proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(jes), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS my hand and official seal.

(Signature of Notary)



Assignor : Patrick Soon-Shiong

Date: February 23, 1998

Signature

Patrick Soon-Shiong

STATE OF California
COUNTY OF Los Angeles

On February 23, 1998 before me, Carol S. Rigsbee, a Notary Public in and for said State, personally appeared Patrick Soon-Shiong, proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(jes), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS my hand and official seal.

(Signature of Notary)
CP6059688.1
102811-990000

COPY

**CERTIFICATE OF AMENDMENT
OF ARTICLES OF INCORPORATION OF
VIVORX PHARMACEUTICAL, INC.,
a California corporation**

ENDORSED - FILED
IN THE OFFICE OF THE
SECRETARY OF STATE
OF THE STATE OF CALIFORNIA

APR 10 1998

BILL JONES, SECRETARY OF STATE

Patrick Saon-Shiong hereby certifies as follows:

1. He is the President and Secretary of VivoRx Pharmaceutical, Inc., a California corporation.
 2. ARTICLE I of the Articles of Incorporation of this corporation is amended to read in full as set forth below:

7

The name of this corporation is American BioScience, Inc."

3. The amendment set forth above in Section 2 of this certificate (the "Amendment") has been duly approved by the Board of Directors of this corporation.

4. The Amendment has been duly approved by the required vote of the shareholders of this corporation in accordance with Section 902 of the California Corporations Code. This corporation has two series Preferred Stock and one class of Common Stock, all of which votes together as one class, and the number of outstanding shares entitled to vote with respect to the Amendment is 48,105,369. The number of shares voting in favor of the Amendment equaled or exceeded the vote required. The percentage vote required for the approval of the Amendment was more than fifty percent (50%).

The undersigned hereby declares under penalty of perjury under the laws of the State of California that he has read this certificate, knows the contents thereof, and that the same is true and correct of his own knowledge.

Executed at Santa Monica, California, on April 9, 1998.

PATRICK SOON-SHIONG,
President and Secretary




Digitized by srujanika@gmail.com

State of California



SECRETARY OF STATE



ing 1 pg.

I, **BILL JONES**, Secretary of State of the State of California,
hereby certify:

That the attached transcript has been compared with
the record on file in this office, of which it purports to
be a copy, and that it is full, true and correct.

IN WITNESS WHEREOF, I execute
this certificate and affix the Great
Seal of the State of California this

APR 14 1998



A handwritten signature in cursive script that reads "Bill Jones".

Secretary of State

Delaware

The First State

COPY


PAGE 1

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF MERGER, WHICH MERGES:

"AMERICAN BIOSCIENCE, INC", A CALIFORNIA CORPORATION, WITH AND INTO "AMERICAN PHARMACEUTICAL PARTNERS, INC." UNDER THE NAME OF "ABRAXIS BIOSCIENCE, INC.", A CORPORATION ORGANIZED AND EXISTING UNDER THE LAWS OF THE STATE OF DELAWARE, AS RECEIVED AND FILED IN THIS OFFICE THE EIGHTEENTH DAY OF APRIL, A.D. 2006, AT 9 O'CLOCK P.M.

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COUNTY RECORDER OF DEEDS.

3430252 8100M
060361520



Harriet Smith Windsor
Harriet Smith Windsor, Secretary of State

AUTHENTICATION: 4676633

DATE: 04-19-06

State of Delaware
 Secretary of State
 Division of Corporations
 Delivered 09:04 PM 04/18/2006
 FILED 09:00 PM 04/18/2006
 SKY 060361520 - 3430252 FILE

**CERTIFICATE OF MERGER
 OF
 AMERICAN BIOSCIENCE, INC.
 INTO
 AMERICAN PHARMACEUTICAL PARTNERS, INC.**

Under Section 252 of the Delaware General Corporation Law ("DGCL")

The undersigned American Pharmaceutical Partners, Inc., a Delaware corporation (the "Company"), DOES HEREBY CERTIFY:

FIRST: That the name and state of incorporation of each of the constituent corporations of the merger is as follows:

<u>Name</u>	<u>State of Incorporation</u>
American BioScience, Inc.	California
American Pharmaceutical Partners, Inc.	Delaware

SECOND: That an agreement and plan of merger between the Company and American BioScience, Inc., dated November 27, 2005 (the "Merger Agreement"), has been approved, adopted, certified, executed and acknowledged by each of the constituent corporations in accordance with Section 252 of the General Corporation Law of the State of Delaware.

THIRD: The Company shall be the surviving corporation of the merger (the "Surviving Corporation"). At the effective time of the merger, the name of the Surviving Corporation will be amended to be Abraxis Bioscience, Inc. as set forth in Article Fourth.

FOURTH: The Amended and Restated Certificate of Incorporation of the Company shall be the Certificate of Incorporation of the Surviving Corporation, with such Amended and Restated Certificate of Incorporation being amended as follows:

(a) Section 1 of the Amended and Restated Certificate of Incorporation is amended to read in its entirety as follows:

"Section 1

The name of the corporation is Abraxis BioScience, Inc. (the "Corporation")."

(b) Section 4.1 of the Amended and Restated Certificate of Incorporation is amended to read in its entirety as follows:

"4.1 The aggregate number of shares of capital stock which the Corporation shall have authority to issue is 356,000,000, consisting of 350,000,000 shares of common stock, \$0.001 par value per share ("Common Stock"), and 6,000,000 shares of preferred stock \$0.001 par value per share ("Preferred Stock")."

Certificate of Merger_v1

FIFTH: The executed Merger Agreement is on file at an office of the Surviving Corporation at 1501 East Woodfield Road, Suite 300 East, Schaumburg, Illinois 60173-5837.

SIXTH: A copy of the Merger Agreement will be furnished by the Surviving Corporation, on request and without cost, to any stockholder of any constituent corporation.

SEVENTH: The authorized capital stock of American BioScience, Inc., the only constituent corporation which is not a Delaware corporation, is 300,000,000 shares of common stock and 32,500,000 shares of preferred stock.

Dated: April 19, 2006

AMERICAN PHARMACEUTICAL PARTNERS, INC.

By:


Name: Patrick Sohn-Shiong
Title: Chief Executive Officer